Talaris Therapeutics to Participate in Two Upcoming Investor Conferences
Talaris Therapeutics, Inc. (Nasdaq: TALS) announced participation in two key investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Talaris Therapeutics, Inc. (Nasdaq: TALS) announced participation in two key investor conferences. The first is the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 1:40 p.m. ET in New York. The second is the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 9:00 a.m. ET, also in New York. A live webcast of the presentations will be available on Talaris' investor website, with replays accessible post-event.
Details
News Market Reaction – TALS
The recorded move for TALS in the trading session of this news was +6.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that members of its senior management team will participate in the following investor conferences:
Morgan Stanley 20th Annual Global Healthcare Conference
Fireside chat date: Monday, September 12, 2022
Fireside chat time: 1:40 p.m. ET
Location: Sheraton Hotel, New York, NY
H.C. Wainwright 24th Annual Global Investment Conference
Presentation date: Wednesday, September 14, 2022
Presentation time: 9:00 a.m. ET
Location: Lotte New York Palace Hotel, New York, NY
A live webcast of the presentations will be available on the investors section of the Talaris website at www.talaristx.com. After the live webcast, a replay of the events can be found on the Talaris website.
About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.
Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783
Investor Contact
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
(339) 970-2843
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.